Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label somatropin in Japanese participants with Prader-Willi syndrome
jRCT2031200351Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of somatropin in Prader-Willi syndrome (PWS) (3 cohorts), sponsored by Pfizer. Primary endpoint: Change from baseline to Month 12 in lean body mass (%) measured by DEXA. Started Feb 2021; status: completed.
02
Drugs
somatropin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on jRCT2031200351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200351.